{
  "source": "PA-Med-Nec-Sotyktu.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2297-5\nProgram Prior Authorization/Medical Necessity\nMedication Sotyktu™ (deucravacitinib)\nP&T Approval Date 1/2023, 4/2023, 7/2023, 7/2024, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSotyktu is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with\nmoderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.\nLimitations of Use:\nNot recommended for use in combination with other potent immunosuppressants.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Sotyktu will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Otezla (apremilast), Skyrizi (risankizumab-rzaa), Stelara\n(ustekinumab), Taltz (ixekizumab), Tremfya (gu",
    ", date, and\nduration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Otezla (apremilast), Skyrizi (risankizumab-rzaa), Stelara\n(ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Sotyktu therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer\nsponsored program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Sotyktu*\n-AND-\n(3) Patient is not receiving Sotyktu in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx),\nCimzia (certolizumab), Cosentyx (secukinumab), Enbrel (etanercept),\nIlumya (tildrakizumab), Olumiant (baricitinib), Orencia (abatacept), Otezla\n(apremilast), Rinvoq (upadacitinib), Siliq (brodalumab), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Taltz\n(ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a manufacturer sponsored program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Sotyktu will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Sotyktu therapy\n-AND-\n(2) Patient is not receiving Sotyktu in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx),\nCimzia (certolizumab), Cosentyx (secukinumab), Enbrel (",
    "y\n-AND-\n(2) Patient is not receiving Sotyktu in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx),\nCimzia (certolizumab), Cosentyx (secukinumab), Enbrel (etanercept),\nIlumya (tildrakizumab), Olumiant (baricitinib), Orencia (abatacept), Otezla\n(apremilast), Rinvoq (upadacitinib), Siliq (brodalumab), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Taltz\n(ixekizumab), Tremfya (guselkumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Sotyktu [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topi",
    "Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n© 2024 UnitedHealthcare Services, Inc.\n3\n7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n9. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\nProgram Prior Authorization/Medical Necessity - Sotyktu (deucravacitinib)\nChange Control\n1/2023 New program\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\npreferred adalimumab products please reference drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n7/2024 Annual review. Updated step therapy criteria requirements. Updat",
    "nce drug coverage tools.”\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n7/2024 Annual review. Updated step therapy criteria requirements. Updated\nstate mandate foot note.\n10/2024 Removed step through preferred products. Added continuation of\ntherapy to initial criteria. Removed preferred adalimumab footnote.\nUpdated examples with no change to clinical intent.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}